查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1625024

2024 年至 2031 年按技術、應用、最終用戶、服務類型和地區劃分的下一代定序 (NGS) 服務市場

Next-Generation Sequencing Services Market By Technology, Application, End-User (Hospitals and Clinics, Contract Research Organizations ), Service Type, & Region for 2024-2031
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

次世代定序 (NGS) 服務市場評估-2024-2031

對次世代定序 (NGS) 服務的需求不斷增長，很大程度上是由於其對個人化醫療和診斷的顛覆性影響。 NGS改變了醫療保健提供者診斷和治療疾病的方式，特別是在腫瘤學、遺傳疾病和傳染病領域。 NGS 可以對整個基因組或選定區域進行快速可靠的測序，從而能夠檢測出可以為有針對性的藥物提供資訊的基因變異，從而使市場在2024 年增長95%。超過33 億美元，達到2031年估值約183.5億美元。

對預防性醫療保健的日益關注推動了對 NGS 服務的需求。隨著醫療保健系統轉向疾病檢測和預防，NGS 提供了全面的基因組篩檢，以識別特定疾病的易感性並實現早期幹預。這在藥物基因組學領域尤其重要，因為NGS可用於預測個體對特定藥物的反應，預計2024年至2031年期間的複合年增長率為21.25%。

次世代定序 (NGS) 服務市場：定義/概述

次世代定序 (NGS) 服務是一種先進的基因組技術，可以快速定序 DNA 或 RNA，以大規模評估遺傳訊息。 NGS 服務為醫學研究、診斷、藥物發現和個人化醫療等廣泛應用所需的基因變異、突變和基因表現提供了關鍵見解。

次世代定序（NGS）服務有許多應用，包括遺傳學、醫學診斷和個人化醫療。最常見的用途之一是基因檢測，它可以識別遺傳的基因異常、突變和疾病傾向。 NGS 能夠對整個基因組或特定區域進行快速、高通量測序，揭示有關癌症、囊性纖維化和心血管疾病等疾病背後的基因突變的大量資訊。

次世代定序 (NGS) 服務的未來應用預計將改變醫療保健的許多方面，包括個人化醫療和基因組學。最有前景的應用之一是癌症診斷和治療，其中NGS可以提供​​詳細的腫瘤分析並找出導致癌症生長的特定基因異常。

推動次世代定序 (NGS) 服務市場採用的關鍵因素有哪些？

次世代定序 (NGS) 服務的採用主要由個人化醫療應用的增加、基因組研究的進步以及定序技術成本的下降所推動。這些特性促進了NGS在各種醫療保健和生命科學應用中的使用。個人化醫療是廣泛採用NGS服務的主要驅動力。根據美國食品藥物管理局（FDA）的數據，截至2022年，過去五年核准的新藥中超過25%是個人化藥物，其中許多是使用NGS技術開發的。

根據美國國家人類基因組研究所（NHGRI）預測，到2022年，人類基因組定序成本預計將下降10萬倍，從2001年的約1億美元降至1,000美元以下。另一個重要因素是NGS在癌症研究和治療上的應用日益廣泛。美國國家癌症研究所的癌症基因組圖譜 (TCGA) 使用 NGS 技術評估了 33 種癌症類型的 20,000 多例原發性癌症和匹配的正常樣本。在腫瘤學領域如此廣泛的應用正在推動NGS服務產業向前發展。

倫理和法律問題是否阻礙了次世代定序（NGS）服務市場的發展？

倫理和法律考量對次世代定序（NGS）服務領域的擴展有重大影響。主要的道德考慮之一是隱私和基因數據的處理。 NGS服務涉及人類基因組定序，會產生敏感的個人資訊，如果不加以妥善保護，這些資訊可能會被濫用。未經授權存取基因數據引發了對濫用的擔憂，例如就業和保險中的基因歧視。

法律問題也對NGS服務業務構成了障礙，特別是在法規合規性和智慧財產權方面。隨著NGS技術的進步，管理基因組資訊使用的法律架構也不斷發展。各國政策不一致阻礙了國際研究合作並限制了市場成長。公司必須遵守複雜的專利法規，特別是有關基因組定序和 NGS 相關技術所有權的法規。此外，圍繞人類基因或特定基因組序列專利的法律糾紛可能會抑制創新並限制獲得關鍵的NGS服務。

目錄

第 1 章 全球次世代定序 (NGS) 服務市場：簡介

  • 市場定義
  • 市場區隔
  • 調查安排
  • 先決條件
  • 限制

第 2 章：經過驗證的市場研究方法

  • 資料探勘
  • 數據三角測量
  • 由下而上的方法
  • 自上而下的方法
  • 調查流程
  • 產業專家的重要見解
  • 資料來源

第 3 章執行摘要

    市場概況
  • 生態製圖
  • 絕對的獲利機會
  • 市場吸引力
  • 全球次世代定序 (NGS) 服務市場：區域分析（CAGR）
  • 全球次世代定序 (NGS) 服務市場按服務類型劃分
  • 全球次世代定序 (NGS) 服務市場（按技術劃分）
  • 全球下一代定序 (NGS) 服務市場（按最終用戶劃分）
  • 全球次世代定序 (NGS) 服務市場（按應用）
  • 未來市場機會
  • 全球市場細分
  • 產品生命線

第 4 章。
  • 全球新一代定序 (NGS) 服務的發展
  • 驅動程式
  • 阻礙因素
  • 機會
  • 波特五力模型
  • 價值鏈分析
  • 價格分析
  • 宏觀經濟分析

5. 全球次世代定序 (NGS) 服務市場（依服務類型）

  • 概述 外顯子定序
  • 標靶重定序與客製化基因組
  • 全基因組定序與從頭定序，RNA-Seq
  • 其他
6. 全球次世代定序 (NGS) 服務市場（按技術）
  • 概述 合成定序
  • 離子半導體定序
  • 單分子即時定序 奈米孔定序

7. 全球下一代定序 (NGS) 服務市場（按最終用戶劃分）

  • 概述
  • 學術與政府機構、研究中心
  • 醫院和診所
  • 製藥和生技公司
  • 其他

8. 全球次世代定序 (NGS) 服務市場（按應用）

  • 概述
  • 診斷
  • 藥物研發
  • 生物標記的發現
  • 農業與動物研究
  • 其他

9. 全球次世代定序 (NGS) 服務市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
    亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

10. 全球次世代定序 (NGS) 服務市場：競爭格局

  • 概述
  • 各公司的市場排名
  • 重大進展
  • 公司地理分佈
  • 公司產業足跡
  • ACE 矩陣

第 11 章 公司簡介

  • Eurofins Scientific
  • illumina, Inc.
  • BGI genomics Co., Ltd.
  • Perkinelmer Inc.
  • Macrogen, Inc.
  • Qiagen N.V.
  • Genewiz
  • Personalis, Inc.
  • Takara Bio Inc.
  • LGC Science Group Holdings Limited

第 12 章 經過驗證的市場研究

    關於 VERIFIED MARKET RESEARCH
  • 動態資料視覺化
簡介目錄
Product Code: 25919

Next-Generation Sequencing (NGS) Services Market Valuation - 2024-2031

The growing demand for next-generation sequencing (NGS) services is largely due to its disruptive impact on personalized medicine and diagnostics. NGS has transformed how healthcare providers approach disease diagnosis and therapy, especially in oncology, genetic disorders, and infectious diseases. NGS enables the speedy and reliable sequencing of complete genomes or select areas allowing the detection of genetic alterations that can inform targeted medicines, hence improving patient outcomes by enabling the market to surpass a revenue of USD 9.53 Billion valued in 2024 and reach a valuation of aroundUSD 18.35 Billion by 2031.

The increased emphasis on preventative healthcare is driving up the demand for NGS services. As healthcare systems turn toward disease detection and prevention, NGS provides comprehensive genomic screening, identifying predispositions to specific ailments and allowing for earlier interventions. This is especially crucial in the field of pharmacogenomics where NGS is used to anticipate how individuals will react to specific pharmaceuticals, hence reducing bad drug responses by enabling the market to grow at aCAGR of 21.25% from 2024 to 2031.

Next Generation Sequencing (NGS) Services Market: Definition/ Overview

Next Generation Sequencing (NGS) services are advanced genomic technologies that enable quick sequencing of DNA or RNA to evaluate genetic information on a massive scale. NGS services give critical insights into genetic variants, mutations, and gene expression which are required for a wide range of applications including medical research and diagnostics, drug discovery, and personalized medicine.

Next Generation Sequencing (NGS) services have numerous uses including genetics, medical diagnostics, and customized medicine. One of the most common applications is genetic testing, which identifies inherited genetic abnormalities, mutations, and disease propensity. NGS enables quick, high-throughput sequencing of entire genomes or particular areas revealing extensive information about genetic variants that contribute to disorders including cancer, cystic fibrosis, and cardiovascular disease.

The future usage of next-generation sequencing (NGS) services is expected to transform numerous aspects of healthcare including personalized medicine and genomics. One of the most promising applications is cancer diagnosis and treatment where NGS may give detailed tumor profiling and pinpoint particular genetic abnormalities that cause cancer growth.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Key Drivers Promoting the Adoption of the Next-Generation Sequencing (NGS) Services Market?

The use of next-generation sequencing (NGS) services is being pushed primarily by increased applications in personalized medicine, advances in genomic research, and lower sequencing technology costs. These characteristics are driving the usage of NGS in a variety of healthcare and life sciences applications. Personalized medicine is a primary driver of NGS service uptake. According to the U.S. Food and Drug Administration (FDA), as of 2022, more than 25% of new pharmaceuticals approved in the past five years were personalized medicines many of which were developed using NGS technologies.

According to the National Human Genome Research Institute (NHGRI), the cost of sequencing a human genome has dropped from approximately USD 100 Million in 2001 to less than $1,000 in 2022, a 100,000-fold decrease. Another key factor is the growing application of NGS in cancer research and treatment. The National Cancer Institute's Cancer Genome Atlas (TCGA) used NGS technology to evaluate over 20,000 primary cancers and matched normal samples from 33 cancer types. This widespread application in oncology is driving the NGS services industry forward.

Will the Ethical and Juridical Concerns Hamper the Next Generation Sequencing (NGS) Services Market?

Ethical and legal considerations have a substantial impact on the expansion of the next generation sequencing (NGS) services sector. One of the main ethical considerations is privacy and the handling of genetic data. Because NGS services include the sequencing of human genomes, sensitive personal information is generated which could be misused if not appropriately protected. Unauthorized access to genetic data raises issues about misuse such as genetic discrimination in employment or insurance.

Legal problems also pose hurdles for the NGS services business, particularly in terms of regulatory compliance and intellectual property rights. As NGS technology progresses, the legal framework governing genomic information use continues to evolve. Inconsistent policies across countries hamper international collaborations and limit market growth. Companies must manage complex patent regulations, particularly those governing ownership of genomic sequences and NGS-related technologies. Furthermore, legal battles over the patenting of human genes or specific genomic sequences can stifle innovation and restrict access to critical NGS services.

Category-Wise Acumens

How Will the Increasing Popularity of Whole Genome Sequencing Drive the Adoption of Next-Generation Sequencing (NGS) Services?

Whole genome sequencing (WGS) is a dominating technology in the next-generation sequencing (NGS) services industry due to its comprehensive nature and wide range of applications across industries. The ability to study genetic variations, mutations, structural changes, and functional elements across the entire genome providing insights into complex biological processes, disease mechanisms, and personalized medicine applications is increasing the use of WGS by researchers, clinicians, and organizations.

In addition, its involvement in discovering novel genetic markers, biomarkers, disease-causing mutations, and therapeutic targets for expanding our understanding of genetic features, hereditary diseases, complex disorders, and genetic predispositions will further accelerate the usage of WGS. In clinical diagnostics and healthcare, WGS is critical for genetic testing, illness diagnosis, and tailored medication. This allows clinicians to identify disease-causing mutations, analyze genetic risk factors, diagnose uncommon genetic illnesses, predict therapy responses, and adapt medicines to individual genomic profiles.

In What Ways are Hospitals and Clinics Driving the Growth of the Next-Generation Sequencing (NGS) Services Market?

The increase in demand for NGS services in hospitals and clinics for a wide range of clinical diagnostic applications including prenatal screening, pharmacogenomics, cancer genomics, rare illness detection, and infectious disease testing is a market profitable factor. NGS enables clinicians to perform the necessity for doctors to conduct complete genomic profiling of patient samples and find genetic mutations, structural variants, and biomarkers to provide accurate prognosis, treatment response, and disease risk data is expected to drive market expansion.

By incorporating genomic information into clinical decision-making, hospitals and clinics can improve treatment outcomes, reduce adverse medication responses, and increase patient happiness and quality of life. Genomic medicine research is widely conducted at hospitals and university medical institutes to improve scientific understanding of hereditary illnesses, molecular pathways, and therapeutic targets. NGS services contribute significantly to genomic research projects by facilitating large-scale DNA sequencing, genome-wide association studies (GWAS), and functional genomics experiments.

Country/Region-wise Acumens

Will the Development of Precision and Tailored Treatments Drive the Market in the North American Region?

North America dominates the next generation sequencing (NGS) services market owing to its advanced healthcare infrastructure and major investments in precision medicine. The Precision Medicine Initiative, initiated by the US government in 2015 with an initial USD 215 Million commitment, has been a significant driver of NGS uptake. The National Institutes of Health's (NIH) "All of Us" Research Program, which is part of this project, seeks to collect genetic data from one million Americans and has already registered over 500,000 people as of 2023.

The NIH's Undiagnosed Diseases Network has employed NGS to diagnose 35% of cases, demonstrating the technology's utility. Furthermore, the Centers for Medicare & Medicaid Services (CMS) enhanced coverage for NGS-based diagnostic tests for individuals with hereditary ovarian or breast cancer in 2020, possibly benefiting up to 100,000 Medicare patients per year. This coverage expansion is projected to dramatically increase the use of NGS services in clinical settings. According to the Centers for Disease Control and Prevention (CDC), more than 1.8 million SARS-CoV-2 genomes will have been sequenced in the United States by 2022, demonstrating the importance of NGS in disease surveillance and pandemic response.

Will the Increasing Demand for Genomic Therapeutics and Whole-Genome Sequencing Drive the Market in the Asia Pacific Region?

The Asia Pacific region is seeing the highest growth in the next generation sequencing (NGS) services market owing to increased demand for genomic therapies and whole-genome sequencing. Significant government funding, increased research activity, and the region's expanding prevalence of genetic illnesses all contribute to its rapid growth. This investment has already paid off with the number of whole-genome sequencing studies in China increasing by 120% between 2015 and 2020, according to the National Center for Biotechnology Information (NCBI).

Another important factor is the region's rising prevalence of genetic diseases. According to the World Health Organization (WHO), the incidence of genetic disorders in Asia is 53.5 per 1,000 live births which is higher than the global average of 39.7. This has resulted in an increased demand for genetic testing and tailored medicine. Since 2017, the South Korean government's Genome Technology to Business Translation Program has invested USD 70 Million in 100 genomics-based startups. Australia's Genomes Health Futures Mission which is part of the Medical Research Future Fund has committed AU$500 million over ten years to genomes research, with AU$150 million already funded by 2023.

Competitive Landscape

The Next Generation Sequencing (NGS) Services Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the next-generation sequencing (NGS) services market include:

Quest Diagnostics Incorporated

ARUP Laboratories

Applied Biological Materials, Inc.

Novogene Co, Ltd.

Azenta Life Sciences (GENEWIZ)

NanoString

Illumina, Inc.

PacBio

Veritas

BGI (Beijing Genomics Institute)

Gene by Gene Ltd.

Lucigen Corporation

Latest Developments

In August 2022, A market leader in clinical diagnostics and life science research introduced a line of type 1 antibodies that prevent the drug evolocumab (Repatha(R)) from binding to its intended target, the human proprotein convertase subtilisin/Kexin type 9 (PCSK9), which has been linked to cholesterol control. These recombinant antibodies with predetermined sequences can be employed to develop highly sensitive and selective evolocumab and biosimilar-specific pharmacokinetic (PK) and anti-drug antibody (ADA) assays.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Next-Generation Sequencing (NGS) Services Market Geographical Analysis (CAGR %)
  • 3.6 Global Next-Generation Sequencing (NGS) Services Market, By Service Type (USD Million)
  • 3.7 Global Next-Generation Sequencing (NGS) Services Market, By Technology (USD Million)
  • 3.8 Global Next-Generation Sequencing (NGS) Services Market, By End-Users (USD Million)
  • 3.9 Global Next-Generation Sequencing (NGS) Services Market, By Application (USD Million)
  • 3.10 Future Market Opportunities
  • 3.11 Global Market Split
  • 3.12 Product Life Line

4 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET OUTLOOK

  • 4.1 Global Next-Generation Sequencing (NGS) Services Evolution
  • 4.2 Drivers
    • 4.2.1 Driver 1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint 1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity 1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY SERVICE TYPE

  • 5.1 Overview
  • 5.2 Exome Sequencing
  • 5.3 Targeted Resequencing & Custom Gene Panels
  • 5.4 Whole-Genome Sequencing & De Novo Sequencing, RNA-Seq
  • 5.5 Others

6 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY TECHNOLOGY

  • 6.1 Overview
  • 6.2 Sequencing By Synthesis
  • 6.3 Ion Semiconductor Sequencing
  • 6.4 Single-Molecule Real-Time Sequencing
  • 6.5 Nanopore Sequencing

7 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY END-USERS

  • 7.1 Overview
  • 7.2 Academic & Government Institutes and Research Centers
  • 7.3 Hospitals & Clinics
  • 7.4 Pharmaceutical & Biotechnology Companies
  • 7.5 Others

8 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY APPLICATION

  • 8.1 Overview
  • 8.2 Diagnostics
  • 8.3 Drug Discovery
  • 8.4 Biomarker Discovery
  • 8.5 Agriculture & Animal Research
  • 8.6 Others

9 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of Latin America
  • 9.6 Middle-East and Africa
    • 9.6.1 UAE
    • 9.6.2 Saudi Arabia
    • 9.6.3 South Africa
    • 9.6.4 Rest of Middle-East and Africa

10 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Developments
  • 10.4 Company Regional Footprint
  • 10.5 Company Industry Footprint
  • 10.6 ACE Matrix

11 COMPANY PROFILES

  • 11.1 Eurofins Scientific
    • 11.2.1 Company Overview
    • 11.2.2 Company Insights
    • 11.2.3 Product Benchmarking
    • 11.2.4 Key Development
    • 11.2.5 Winning Imperatives
    • 11.2.6 Current Focus & Strategies
    • 11.2.7 Threat from Competition
    • 11.2.8 SWOT Analysis
  • 11.2 illumina, Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Insights
    • 11.3.3 Product Benchmarking
    • 11.3.4 Key Development
    • 11.3.5 Winning Imperatives
    • 11.3.6 Current Focus & Strategies
    • 11.3.7 Threat from Competition
    • 11.3.8 SWOT Analysis
  • 11.3 BGI genomics Co., Ltd.
    • 11.3.1 Company Overview
    • 11.3.2 Company Insights
    • 11.3.3 Product Benchmarking
    • 11.3.4 Key Development
    • 11.3.5 Winning Imperatives
    • 11.3.6 Current Focus & Strategies
    • 11.3.7 Threat from Competition
    • 11.3.8 SWOT Analysis
  • 11.4 Perkinelmer Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Insights
    • 11.4.3 Product Benchmarking
    • 11.4.4 Key Development
    • 11.4.5 Winning Imperatives
    • 11.4.6 Current Focus & Strategies
    • 11.4.7 Threat from Competition
    • 11.4.8 SWOT Analysis
  • 11.5 Macrogen, Inc.
    • 11.5.1 Company Overview
    • 11.5.2 Company Insights
    • 11.5.3 Product Benchmarking
    • 11.5.4 Key Development
    • 11.5.5 Winning Imperatives
    • 11.5.6 Current Focus & Strategies
    • 11.5.7 Threat from Competition
    • 11.5.8 SWOT Analysis
  • 11.6 Qiagen N.V.
    • 11.6.1 Company Overview
    • 11.6.2 Company Insights
    • 11.6.3 Product Benchmarking
    • 11.6.4 Key Development
    • 11.6.5 Winning Imperatives
    • 11.6.6 Current Focus & Strategies
    • 11.6.7 Threat from Competition
    • 11.6.8 SWOT Analysis
  • 11.7 Genewiz
    • 11.7.1 Company Overview
    • 11.7.2 Company Insights
    • 11.7.3 Product Benchmarking
    • 11.7.4 Key Development
    • 11.7.5 Winning Imperatives
    • 11.7.6 Current Focus & Strategies
    • 11.7.7 Threat from Competition
    • 11.7.8 SWOT Analysis
  • 11.8 Personalis, Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Company Insights
    • 11.8.3 Product Benchmarking
    • 11.8.4 Key Development
    • 11.8.5 Winning Imperatives
    • 11.8.6 Current Focus & Strategies
    • 11.8.7 Threat from Competition
    • 11.8.8 SWOT Analysis
  • 11.9 Takara Bio Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Insights
    • 11.9.3 Product Benchmarking
    • 11.9.4 Key Development
    • 11.9.5 Winning Imperatives
    • 11.9.6 Current Focus & Strategies
    • 11.9.7 Threat from Competition
    • 11.9.8 SWOT Analysis
  • 11.10 LGC Science Group Holdings Limited
    • 11.10.1 Company Overview
    • 11.10.2 Company Insights
    • 11.10.3 Product Benchmarking
    • 11.10.4 Key Development
    • 11.10.5 Winning Imperatives
    • 11.10.6 Current Focus & Strategies
    • 11.10.7 Threat from Competition
    • 11.10.8 SWOT Analysis

12 VERIFIED MARKET RESEARCH

  • 12.1 About Verified Market Research
  • 12.2 Dynamic Data Visualization